Rocklatan® Evaluation
Part of paid clinical trials in Mission Hills, California.
- Sponsor
- Aerie Pharmaceuticals
- Study ID
- NCT05283395
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution — DRUGCommercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Study Details
The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).
Key Dates
- Start date
- Mar 28, 2022
- Status verified
- Jan 2024
- Primary completion
- Mar 22, 2023
- Completion
- Mar 22, 2023
Study Design
- Enrollment
- 136 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: RocklatanNetarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, one drop in each eye in the evening for 12 weeks
Primary Outcome Measure
Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 [ Time Frame: Baseline (Day 0 pretreatment), Week 12 ]
Locations (21)
Find similar trials in Mission Hills, CA
By condition
By specialty
Related Studies
- Novel Glaucoma DiagnosticsRecruiting · Wills Eye · Philadelphia, Pennsylvania
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut
- Village-Integrated Eye Worker Trial IIRecruiting · University of California, San Francisco · San Francisco, California
- Pilocarpine Use After Kahook GoniotomyPHASE3 · Recruiting · Montefiore Medical Center · The Bronx, New York